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Mice fedahigh-fat, low-carbohydrateketogenic
diet (KD) exhibit marked changes in hepatic
metabolism and energy homeostasis. Here, we
identify liver-derived fibroblast growth factor
21 (FGF21) as an endocrine regulator of the
ketotic state. Hepatic expression and circulat-
ing levels of FGF21 are induced by both KD
and fasting, are rapidly suppressed by refeed-
ing, and are in large part downstreamof PPARa.
Importantly, adenoviral knockdown of hepatic
FGF21 inKD-fedmicecauses fatty liver, lipemia,
and reduced serum ketones, due at least in part
to altered expression of key genes governing
lipid and ketone metabolism. Hence, induction
of FGF21 in liver is required for the normal acti-
vation of hepatic lipid oxidation, triglyceride
clearance, and ketogenesis induced by KD.
These findings identify hepatic FGF21 as a criti-
cal regulator of lipid homeostasis and identify
a physiological role for this hepatic hormone.
INTRODUCTION
The control of hepatic lipid metabolism is an intricate
process requiring regulation of lipid synthesis, uptake,
conversion to other fuels, oxidation, and release into the
circulation. Key regulatory factors include hormones
such as insulin; metabolites such as free fatty acids; and
nuclear receptors and regulatory molecules such as per-
oxisome proliferator-activated receptor a (PPARa), liver
X receptor (LXR), and sterol regulatory element-binding
protein 1c (SREBP1c) (Kalaany and Mangelsdorf, 2006;
Jump et al., 2005; Li and Glass, 2004; Reddy and Hashi-
moto, 2001). During periods of fasting, hepatic metabo-
lism is programmed to oxidize fatty acids and to deliver
fuel in the form of ketone bodies that progressively
become the predominant energy source for the brain.
Feeding rodents a high-fat, very low-carbohydrate keto-426 Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc.genic diet (Bough and Eagles, 1999) also induces lipid
oxidation and ketosis and is associated with weight loss
(Kennedy et al., 2007; Thio et al., 2006). Although profound
physiological changes associated with the ketogenic diet
have been described in mice, the responsible regulatory
mechanisms have yet to be determined (Kennedy et al.,
2007). Similarly, many changes in hepatocellular metabo-
lism have been characterized during ketosis, as have
causative changes in the extrahepatic hormonal milieu,
such as falling insulin and rising glucagon levels. However,
little is known as to whether the hepatocytes themselves
participate actively by releasing a paracrine or endocrine
signal of their metabolic status.
Using microarray analysis to assess hepatic gene
expression, we identified fibroblast growth factor 21
(FGF21) as a transcript encoding a protein with an extra-
cellular signaling role that is significantly increased in
mice fed a ketogenic diet. FGF21 is a recently described
210 amino acid member of the FGF superfamily
expressed predominantly in the liver (Nishimura et al.,
2000). In common with its close homologs human
FGF19 and murine FGF15, FGF21 has been ascribed
a metabolic role (Tomlinson et al., 2002; Fu et al., 2004;
Kharitonenkov et al., 2005). The first suggestion that
FGF21 has a metabolic effect came from high-throughput
screening of agents capable of increasing glucose uptake
in the 3T3-L1 adipocyte cell line. Subsequent analysis
revealed that exposure of adipocytes to FGF21 increases
expression of GLUT1, thereby stimulating insulin-
independent glucose uptake. Prompted by this finding,
FGF21 was tested in diabetic animal models. In ob/ob
(Kharitonenkov et al., 2005) and db/db (Kharitonenkov
et al., 2007) mice, exogenous FGF21 reduced the glucose
excursion following an oral glucose load, with a lower
peak insulin response, consistent with increased insulin-
independent glucose uptake. Notably, transgenic mice
overexpressing FGF21 are protected from diet-induced
obesity and have smaller adipocytes and more brown
adipose tissue (Kharitonenkov et al., 2005). Administration
of FGF21 to diabetic rhesus monkeys improved their
circulating lipid profiles and lowered fasting glucose
(Kharitonenkov et al., 2007). Although the effects of
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olism are of considerable interest, the mechanisms
regulating FGF21 expression and its physiological role
are not understood.
We report here the results of studies that identify key
elements of the nutritional and physiological regulation
of hepatic FGF21 expression. Furthermore, by using short
hairpin RNA-mediated knockdown of hepatic FGF21 gene
expression in mice on a ketogenic diet, we establish a
critical role for FGF21 in hepatic fuel homeostasis. Specif-
ically, the results demonstrate that hepatic FGF21 is a crit-
ical molecular intermediate between diet, PPARa, and the
physiological regulation of hepatic and systemic lipid
metabolism.
RESULTS
FGF21 Is a Signaling Molecule Induced
in the Ketotic State
Microarray analysis was performed to identify changes in
murine hepatic gene expression following feeding of
a high-fat, low-carbohydrate ketogenic diet (KD) for 30
days. While on KD, mice lost approximately 4.5 g com-
pared to chow-fed animals during the first 7 days after
diet initiation and thereafter maintained stable weight
below that of chow-fed animals for 30 days. Specific inter-
rogation of a subset of transcripts upregulated by KD
feeding was performed in order to identify genes with
a molecular function involving a potential signaling role.
Generation of a gene ontology tree by molecular function
(see Table S1 in the Supplemental Data available with this
article online) revealed 43 upregulated genes involved in
signal transduction, of which 8 had receptor binding activ-
ity. Of all transcripts with signal transducer activity, FGF21
was the most upregulated; expression was increased by
18.5-fold (90% lower confidence bound 9.3; Figure 1A).
Quantitative PCR (qPCR) confirmed >25-fold induction
of FGF21 mRNA in livers of mice that had been fed KD
for 3 or 30 days (Figure 1B). Preliminary analysis of the mi-
croarray data set also suggested an upregulation of
PPARa-regulated transcripts. Therefore, we expanded
our search strategy to include gene set enrichment analy-
sis (GSEA; Subramanian et al., 2005), which revealed that
a set of genes known to be regulated by PPARa was also
significantly upregulated by KD (Figure 1C). Furthermore,
qPCR analysis of gene expression in mice fed KD for 30
days revealed significant elevation of several classical
PPARa-regulated targets (Figure 1D).
Induction of FGF21 during Fasting Parallels Ketosis
In order to establish the specific effects of fasting on
FGF21 levels, previously chow-fed mice were fasted
from the onset of the light cycle for a maximum of 24 hr.
Ketosis was fully induced at 24 hr (Figure 2A) and was as-
sociated with a 30% increase in nonesterified fatty acids
(NEFAs; Figure 2B). Induction of ketosis corresponded
to maximal induction of FGF21 mRNA (Figure 2C). Re-
feeding of fasted mice rapidly suppressed ketosis and cir-
culating NEFAs (Figures 2D and 2E). These changes wereparalleled by markedly reduced FGF21 expression at 1 hr
of refeeding, with expression levels returning to fed levels
at 8 hr (Figure 2F). The dynamics of circulating FGF21
reflected that of gene expression, as serum FGF21 was
elevated after fasting and rapidly suppressed on refeed-
ing, returning to fed levels after 8 hr (Figure 2G).
Fenofibrate and Fatty Acids Induce FGF21 In Vitro
Since both FGF21 and classical PPARa-regulated genes
were induced by KD, we tested the hypothesis that
PPARa directly induces FGF21. As fenofibrate has pleio-
tropic effects in vivo, primary hepatocytes were isolated
from C57BL/6 mice and treated with this PPARa agonist.
FGF21 expression was induced by 100 mM fenofibrate
(Figure 2H). To assess the potential role of dietary compo-
nents of KD, isolated primary hepatocytes were exposed
to the major fatty acid components of KD conjugated to
bovine serum albumin. After 24 hr exposure, cells were
viable, and the exclusion of vital dyes was not changed
by any fatty acid treatment. Oleic acid, the predominant
fatty acid in this KD, significantly increased FGF21
mRNA expression in vitro (Figure 2I).
Figure 1. FGF21 Is Upregulated in Livers of KD-Fed Mice
Together with Transcripts for Other PPARa-Regulated Genes
(A) Output from microarray revealed significant induction of FGF21 in
livers frommice fed a ketogenic diet (KD) for 30 days. (n = 3 per group;
*p < 0.05.) In this and all other figures, error bars represent mean ±
SEM.
(B) Confirmation of altered expression by qPCR analysis. Induction
of FGF21 (normalized to cyclophilin) by KD occurred after feeding
for 72 hr. Similar >25-fold induction was seen after 30 days of KD.
(n = 6–8 per group; *p < 0.05.)
(C) GSEA heat map shows a significant enrichment of PPARa targets
within transcripts upregulated by KD feeding (red) in KD versus chow
conditions.
(D) qPCR confirmation of upregulation of PPARa targets. Multiple clas-
sical PPARa-responsive genes were induced (normalized to cyclophi-
lin) by KD feeding, including uncoupling protein 2 (UCP2), fatty acid
translocase (FAT/CD36), and the members of the ATP-binding cas-
sette family ABCD2 and ABCB4. (n = 6–8 per group; *p < 0.05.)Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc. 427
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(A) b-hydroxybutyrate levels increased significantly between 8 and 24 hr of fasting. In (A)–(G), n = 6 animals per group; *p < 0.05 versus control or t = 0.
(B) A significant increase in circulating nonesterified fatty acids (NEFAs) was seen after 24 hr of fasting.
(C) FGF21 induction (normalized to cyclophilin) paralleled the time course of increases in serum b-hydroxybutyrate andNEFAs. Significant elevation of
FGF21 levels was noted only after 24 hr of fasting.
(D) After 48 hr of fasting, there was significant elevation of circulating b-hydroxybutyrate, which was rapidly suppressed upon refeeding to reach fed
levels within 1 hr.
(E) Circulating NEFA levels following fasting and refeeding. The time course of NEFA clearancewas also rapid, with NEFA returning to fed levels within
1 hr of refeeding.
(F) Expression of FGF21 (normalized to cyclophilin) following refeeding after a 48 hr fast. A rapid reduction in expression of FGF21was noted after 1 hr
of refeeding; fasting expression levels were attained 8 hr after refeeding.
(G) Serum FGF21 levels as assessed by radioimmunoassay (RIA) were elevated after a 48 hr fast and rapidly suppressed after chow refeeding,
returning to fed levels after 8 hr.
(H) qPCR analysis of FGF21 expression (normalized to cyclophilin). In order to establish direct regulation of FGF21 by PPARa, isolated hepatocytes
were serum starved and subsequently exposed to either 100 mM fenofibrate or vehicle for 2 hr. In (H) and (I), n = 4 culture dishes per group; *p < 0.05.
(I) qPCR analysis of FGF21 expression (normalized to cyclophilin) following exposure of isolated hepatocytes to BSA-conjugated fatty acids. No
stimulation was noted with lauric acid (C12) or palmitic acid (C16). A modest elevation was seen with stearic acid (C18) and linoleic acid (C18:2).
The greatest increase was seen in cells treated with oleic acid (C18:1).PPARa Null Mice Are FGF21 Deficient
and Compromised during Ketosis
To determine whether PPARa is required in vivo for
FGF21 response to ketosis, chow-fed PPARa null
129S4/SvJae-Pparatm1Gonz/J mice and control 129S1/
SvImJ mice were maintained on chow, changed to
KD, or fasted. There was no difference in total caloric in-
take between chow- or KD-fed mice over a 4 day period
of feeding. In support of the critical role of PPARa in
regulating FGF21 expression, there was a striking
absence of hepatic FGF21 mRNA in PPARa null mice428 Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Incunder chow-fed or fasted conditions. Similarly, induction
of FGF21 expression by KD was markedly reduced in
PPARa null mice. However, although the magnitude of
induction was less, FGF21 expression did increase in re-
sponse to KD in PPARa null mice, demonstrating that
PPARa-independent mechanisms for the induction of
FGF21 do exist (Figure 3A). Circulating FGF21 levels
also paralleled gene expression under these conditions
(Figure 3B).
Notably, PPARa null mice lacking FGF21 had a mark-
edly reduced body temperature when fasting compared.
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(A) Expression of FGF21 (normalized to cyclophilin) in control and PPARa null fed, fasted, or KD-fed mice. PPARa null mice did not express FGF21 in
the chow-fed state or following a 24 hr fast. In contrast, KD-fed PPARa null mice exhibited a substantial, though attenuated, induction in FGF21
expression. (n = 5 per group; *p < 0.05.)
(B) Circulating FGF21 levels paralleled hepatic gene expression. Fasting induced a significant increase in circulating levels only in wild-type mice, and
increased circulating FGF21 was detectible in KD-fed PPARa null mice.
(C) After 24 hr of fasting, both control and PPARa null mice lost an equivalent amount of weight. The weight loss on KD feeding was less in wild-type
animals than in PPARa null animals.
(D) Glucose decreased with both fasting and KD feeding in PPARa null mice.
(E) b-hydroxybutyrate failed to increase in fasted PPARa null mice. An increase was seen in both groups of animals when fed KD.
(F) No significant differences were noted in circulating triglycerides in the fasted or KD-fed states.
(G) While NEFA levels were the same in chow-fed or fasted wild-type animals, they were significantly elevated in fasted or KD-fed PPARa null mice.
(H) No significant changes in circulating cholesterol were observed.
(I) Gross appearance of liver (left lobe depicted) showsmarked increase in size of the liver, reflecting fat accumulation in fasted andKD-fedPPARa nullmice.
(J) Histological analysis showed no difference between control and PPARa null mice in the chow-fed state. Fasting increased fat accumulation in the liver of
PPARa null mice. KD feeding caused accumulation of fat in a microvesicular pattern in control mice; there were marked changes in the pattern of fat accu-
mulation in KD-fed PPARa null mice. Scale bar = 50 mm.
(K) Total hepatic triglyceride content of liver showed a marked increase in triglyceride accumulation in the livers of fasted or KD-fed PPARa null mice and
paralleled gross changes.Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc. 429
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0.5C). In contrast, PPARa null mice had normal core
temperature during KD feeding (37.9C ± 0.2C versus
37.5C± 0.1C).Weight loss in response to KDwas some-
what increased in the PPARa null mice (Figure 3C). During
fasting, PPARa null mice developed relative hypoglycemia
and failed to enter a ketotic state (Figures 3D and 3E).
Feeding PPARa null mice KD also resulted in reduced
circulating glucose levels and a modest but significant
reduction in circulating ketone levels in the face of unal-
tered circulating triglycerides or total cholesterol (Figures
3D–3H). Importantly, on KD, PPARa null mice developed
livers with a severe fatty appearance at the gross and his-
tological levels (Figures 3I and 3J). These changes were
more marked than the lipid accumulation in the liver of
fasted PPARa null mice, and their livers represented
a higher proportion of body weight. Likewise, biochemical
analysis revealed a significant increase in hepatic triglyc-
eride content in PPARa null mice both when fasting and
when fed KD (Figure 3K). Thus, PPARa null mice have sim-
ilar directional changes with respect to FGF21 expression,
hepatic lipid accumulation, ketone levels, and glucose
levels whether challenged by fasting or by KD. This raised
the possibility that the induction of hepatic FGF21 might
play a causative role in a subset of the metabolic changes
induced by KD.
Knockdown of FGF21 Results in Severe Metabolic
Abnormalities
To assess the physiological role of FGF21, we employed
adenovirus-mediated expression of short hairpin RNA di-
rected against FGF21 (shFGF21) or an unrelated gene,
LacZ (shLacZ). Adenovirus-mediated FGF21 knockdown
that had previously been validated in vitro reduced the
KD-mediated induction of FGF21 by 72% in vivo
(Figure 4A). This was associated with a significant de-
crease in circulating FGF21 levels (Figure 4B). Gross
changes in hepatic appearance were notable 3 days after
administration of virus. Livers became pale, friable, and
fatty in nature (Figure 4C); fat accumulation was evident
at a histological level (Figure 4D). The change in appear-
ance was matched by increased hepatic triglyceride con-
tent (Figure 4E).
Importantly, the serum from FGF21 knockdownmice on
KD was extremely lipemic and showed a marked increase
in triglyceride levels and a 40% increase in total choles-
terol (Figures 5A–5C). Circulating NEFAs were also
elevated following FGF21 knockdown, and a significant
reduction in serum ketones was also apparent (Figures
5D and 5E), though as in the PPARa null mice on KD,
this was a relatively modest change and was not associ-
ated with a significant change in glycemia (Figure 5F) or
core temperature. Further analysis of circulating lipids in
the fed state by fast protein liquid chromatography
(FPLC) revealed that the hypertriglyceridemia was pre-
dominantly due to increases in the triglyceride-rich chylo-
micron/very low density lipoprotein (VLDL) fraction
(Figure 5G). This was confirmed by separate density-gra-
dient ultracentrifugation analysis (data not shown).430 Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc.Figure 4. Effect of FGF21 Knockdown in the Ketotic State
(A) qPCR confirmation of changes in FGF21 mRNA (normalized to
18S). Hepatic FGF21 expression decreased by 70% following treat-
ment with shFGF21. (n = 5 per group; *p < 0.05.)
(B) Analysis of circulating levels of FGF21 by RIA revealed a significant
increase in circulating FGF21 due to KD feeding; circulating levels were
reduced by treatment with shFGF21.
(C) Gross appearance of livers (left lobe depicted) from adenovirus-
treated mice. The difference in appearance between chow-fed and
KD-fed shLacZ-treated mice reflects the expected accumulation of
lipid seen in noninfected animals. The fatty appearance of the liver
was substantially more marked in mice injected with shFGF21. Scale
bar = 5 mm.
(D) Histological analysis of adenovirus-treated mice revealed in-
creased lipid accumulation in KD-fed mice; this was more marked in
mice treated with shFGF21. Scale bar = 50 mm.
(E)Triglyceridecontent of liver. Triglycerideaccumulationwas increased
in KD-fed mice, and there was a notable increase in total triglyceride
accumulation in the livers of KD-fed mice treated with shFGF21.
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(A) Serum from KD-fed mice injected with either shLacZ control or shFGF21. FGF21 knockdown was associated with onset of extremely lipemic
serum.
(B–F) Significant elevations in triglycerides (B), cholesterol (C), and NEFAs (D) were seen in KD-fed mice treated with shFGF21 adenovirus compared
to mice treated with control shLacZ virus. There were modest but statistically significant decreases in circulating b-hydroxybutyrate (E) and glu-
cose (F) levels in KD-fed mice that trended lower than in chow-fed mice and were not altered by FGF21 knockdown. (n = 6–8 per group; *p < 0.05.)
(G) FPLC analysis shows a substantial increase in triglycerides in the chylomicron/VLDL fraction in KD-fed shFGF21-treated animals.
(H) Plasma triglycerides of KD-fed shFGF21-treated mice were substantially elevated after 4 days compared to control virus-treated mice.
(I) In KD-fed mice treated with control virus in which circulating triglycerides were low, treatment with the LPL inhibitor tyloxapol led to significant
increase in circulating triglycerides (6-fold icnrease within 6 hr of injection) in the fed state. In mice receiving shFGF21 virus, plasma triglycerides
were high, and tyloxapol did not change these levels. (Percent change from baseline shown.)In order to establish whether the hyperlipidemic pheno-
type of KD-fed FGF21 knockdown animals was primarily
due to overproduction or to defective clearance of triglyc-
eride-rich particles including chylomicrons and VLDLs, we
utilized the lipoprotein lipase (LPL) inhibitor tyloxapol (Petit
et al., 2007). Plasma triglycerides were 5-fold higher in
shFGF21 adenovirus-treated animals, and there was no
further increase in this level following injection of tyloxapol
(Figures 5H and 5I). In contrast, tyloxapol administration to
control virus-treated mice led to a steady increase in lipe-
mia such that, at 6 hr after injection, plasma triglycerides
were elevated to a level seen in shFGF21-treated mice
(Figure 5I).
Changes in Hepatic Gene Expression Induced
by Knockdown of FGF21
In an effort to understand the cause of hepatic fat accumu-
lation and lipemia after FGF21 knockdown, expression of
molecules involved in hepatic lipid handling was quanti-Cfied by qPCR. Knockdown of FGF21 was associated
with reduction of KD-mediated induction of genes in-
volved in b-oxidation, including very long (ACADVL),
long (ACADL), and medium (ACADM) chain acetyl-CoA
dehydrogenase and the b subunit of the mitochondrial tri-
functional protein, hydroxyacyl-CoA dehydrogenase
(HADH) (Figures 6A–6D). In addition, FGF21 knockdown
was associated with reduction in expression of carnitine
palmitoyltransferase 1a (CPT1a) and acyl-CoA oxidase
(ACOX1) (Figures 6E and 6F). On the other hand, FGF21
knockdown had no effect on KD-mediated suppression
of genes associated with lipid synthesis, including hydrox-
ymethylglutaryl-CoA reductase (HMGR; Figure S1), fatty
acid synthase, and SCD1 (data not shown), or cholesterol
efflux, including ABCA1 (Figure S1). KD also induced the
fatty acid transporter CD36, and this was significantly
reduced by FGF21 knockdown (Figure 6G). Although the
impairment of ketosis following adenoviral FGF21 knock-
down was relatively modest, quantitation of transcripts ofell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc. 431
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All gene expression was assessed by qPCR and normalized to 18S RNA.
(A–C) Expression of enzymes involved in fatty acid oxidation including acyl-CoA dehydrogenase very long chain (ACADVL; [A]), long chain (ACADL;
[B]), andmedium chain (ACADM; [C]) was elevated by KD feeding. FGF21 knockdown led to a return to chow-fed levels. (n = 6–8 per group; *p < 0.05.)
(D) Hydroxyacyl-CoA dehydrogenase (HADH) was significantly induced by KD; there was amodest but statistically significant decrease in expression
in shFGF21-treated versus shLacZ-treated KD-fed animals.
(E and F) FGF21 knockdown led to a small but significant decrease in carnitine palmitoyltransferase 1a (CPT1a) and acyl-CoA oxidase (ACOX1)
expression in KD-fed animals.
(G) Fatty acid translocase/CD36 was markedly induced by KD feeding, an effect partially reversed by FGF21 knockdown.
(H) Hydroxymethylglutaryl-CoA synthase 2 expression (HMGCS2) was significantly induced by KD feeding; treatment with shFGF21 returned expres-
sion to chow-fed levels.
(I) Treatment with shFGF21 produced a significant reduction in expression of 3-hydroxybutyrate dehydrogenase (BDH1).enzymes involved in the ketogenic pathway and induced
by KD including hydroxymethylglutaryl-CoA synthase 2
(HMGCS2) and 3-hydroxybutyrate dehydrogenase (BDH)
were also reduced (Figures 6H and 6I).
The effects of FGF21 knockdown on LPL expression
were investigated in metabolically active tissues. This
revealed that after exposure to shFGF21 adenovirus,
expression of LPL was elevated in liver, unchanged in
skeletal muscle, and mildly reduced in adipose tissue
(Figure S2). Changes in mRNA levels for two recently dis-
covered modulators of systemic lipid metabolism, angio-
poietin-like peptides 3 (ANGPTL3) and 4 (ANGPTL4),432 Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Incwere quantitated by qPCR (Figure S2). KD feeding was
associated with a reduction of the LXR target ANGPTL3,
and further reduction of this transcript was noted follow-
ing FGF21 knockdown. Conversely, while there was no
significant change in ANGPTL4 induced by KD feeding,
FGF21 knockdown caused an increase in ANGPTL4
mRNA.
DISCUSSION
Numerous hormones, substrates, and intracellular regula-
tory factors contribute to the regulation of hepatic fuel.
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et al., 2005), but it is possible that important factors remain
to be identified. Recently, we used a high-fat/very low-
carbohydrate ketogenic diet (Bough and Eagles, 1999) in
mice to analyze a distinctive metabolic state, character-
ized by weight loss, sustained ketogenesis, and induction
of hepatic lipid oxidation, among other changes (Kennedy
et al., 2007). Because the physiological changes that we
observed in KD-fed mice did not seem to be fully
explained by known hormonal regulators, we assessed
hepatic gene expression in KD-fed mice by Affymetrix
arrays in the attempt to identify novel regulators of hepatic
function. Using an approach designed to identify secreted
proteins, we found that FGF21 was markedly induced in
livers of KD-fed mice. FGF21 was also found to be
induced by starvation and suppressed by refeeding, and
multiple criteria indicate that its expression is at least in
part downstream of PPARa. Importantly, using in vivo
suppression of hepatic FGF21 expression with shRNA-
expressing adenovirus, we found that induction of
FGF21 is required for the liver to fully regulate hepatic lipid
metabolism in response to this nutritional challenge. In the
accompanying paper by Inagaki et al. (2007) in this issue
of Cell Metabolism, complementary gain-of-function
experiments demonstrate that FGF21 regulates diverse
processes associated with fasting, including lipolysis,
ketosis, and torpor. Thus, these two approaches demon-
strate a PPARa-FGF21 pathway that regulates metabo-
lism in response to fasting or ingestion of KD.
PPARa is the nuclear receptor most responsible for
orchestrating the response of lipid oxidation and ketogen-
esis in liver, particularly in response to systemic signals
during starvation (Kersten et al., 1999; Leone et al.,
1999). PPARa activity is at least in part regulated by fatty
acid ligands, which can activate this nuclear receptor
(Chakravarthy et al., 2005). Once activated, PPARa binds
to the promoters of many genes to activate them, includ-
ing those required for lipid oxidation and ketogenesis. In
support of this conclusion, when mice lacking PPARa
are fasted, they develop fatty liver due to impaired induc-
tion of genes required for fat oxidation and have reduced
ketogenesis due at least in part to impaired activation of
rate-limiting genes of ketogenesis (Kersten et al., 1999;
Leone et al., 1999). In the current study, when PPARa
null mice were placed on KD, we observed effects on lipid
metabolism that paralleled those seen with starvation.
Based on prior understanding, it would not have been
expected that full induction of a subset of PPARa-
regulated genes in vivo would require the expression of
a PPARa-dependent hepatic secreted signaling protein
as an intermediary, but such a conclusion is what our
findings seem to indicate. First, FGF21 expression is
regulated in vitro by synthetic PPARa ligands and free
fatty acids, and its expression is suppressed in PPARa
null mice fed either chow diet or KD. Furthermore,
shRNA-mediated partial knockdown of hepatic FGF21 ex-
pression during KD limits key changes in expression of
genes known to be directly responsive to PPARa. It is
known that PPARa directs expression of genes of lipidmetabolism expression by binding to promoters of spe-
cific genes. Our findings suggest that a second mecha-
nism is also involved, whereby PPARa induces expression
of FGF21, which then, in a paracrine and/or endocrine
fashion and by an as yet uncertain signaling mechanism
likely involving a membrane receptor, contributes to the
expression of the relevant genes. Whether this represents
a more general mechanism to mediate or amplify gene
expression regulated by nuclear receptors or is limited
to this example in the PPARa pathway is unknown and
will require further study. Whether FGF21 acts through
one of the previously identified FGF receptors or an as
yet unidentified receptor is also an important topic for
future research. Likewise, the mechanism by which the
FGF21-dependent signals act independently of or in
cooperation with PPARa to regulate gene expression is
currently unknown.
Our observation that FGF21 plays a role in metabolic
regulation downstream of PPARa during ketogenic states
adds importantly to the limited knowledge regarding this
recently described member of the FGF gene family. An
increasing body of evidence indicates that FGF21 is capa-
ble of exerting metabolic actions when administered to
mice or nonhuman primates. Addition of FGF21 to differ-
entiated 3T3-L1 adipocytes increases glucose uptake
via induction of GLUT1 expression (Kharitonenkov et al.,
2005). Systemic administration of FGF21 reduces glucose
levels and improves lipid levels in mice and primates in the
fed state (Kharitonenkov et al., 2007), and transgenic mice
overexpressing FGF21 in the liver are resistant to the
effects of a high-fat diet (Kharitonenkov et al., 2005). How-
ever, despite these important pharmacologic insights,
a physiological role for FGF21 has yet to be described.
FGF21 is expressed predominantly in liver, but we find
that its expression is very low in the fed state. Our data
indicate that hepatic FGF21 is induced both by starvation
and by the ketogenic state induced by a high-fat/low-
carbohydrate diet. In both of these states, increased b-
oxidation of free fatty acids is induced, as increased reli-
ance on lipid fuels is necessary for production of glucose
and ketone bodies. It appears that FGF21 plays a critical
role in allowing this hepatic metabolic program to be
carried out. The full identity of genes and pathways down-
stream of FGF21 in liver and the potential physiological
relevance of FGF21’s actions in other target tissues,
such as adipose tissue, will require additional study.
A biochemical explanation for the changes in lipid me-
tabolism that we observed inmice on KD after knockdown
of FGF21 requires discussion. Modest hepatic accumula-
tion of triglycerides is a feature of KD feeding; however, tri-
glyceride accumulation was much greater after FGF21
knockdown. We therefore determined the effects of
FGF21 knockdown on gene expression of key enzymes
in pathways of lipid oxidation known to be altered by KD
that could account for these changes. Expression analysis
of several rate-limiting genes for b-oxidation revealed
a near complete reversal of KD-mediated changes after
FGF21 knockdown. In particular, expression of key
PPARa targets that potentiate production of acetyl CoACell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc. 433
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and long- or medium-chain acyl-CoA dehydrogenase.
Targets that effect production of ketones, e.g., 3-hydrox-
ybutyrate dehydrogenase, were also affected. It is there-
fore likely that under the circumstances of FGF21 knock-
down, a major cause of fatty liver is the reduced
capacity of the liver to oxidize lipid substrate. It is also pos-
sible that the fatty liver seen after FGF21 knockdown
might be secondary to the actions of FGF21 on other tis-
sues, including adipose tissue.
What is the mechanism for marked serum hypertrigly-
ceridemia in KD-fed mice after knockdown of FGF21?
The increase in plasma triglyceride levels in KD-fed mice
after FGF21 knockdown is predominantly in the triglycer-
ide-rich chylomicron/VLDL fraction. Therefore, one possi-
ble explanation is that in the face of heavy dietary lipid in-
take on KD, FGF21 normally acts to facilitate clearance of
dietary lipids residing within the chylomicron/VLDL frac-
tion via the action of LPL. The importance of LPL in pro-
tecting KD-fed mice from hypertriglyceridemia is sup-
ported by the fact that when KD-fed mice are treated
with the LPL inhibitor tyloxapol, they rapidly develop se-
vere hypertriglyceridemia. Furthermore, tyloxapol admin-
istered to KD-fed FGF21 knockdown mice produces no
additional elevation in triglyceride levels. Thus, it is also
possible that impairment of VLDL secretion contributes
to the hepatic accumulation of triglycerides following
FGF21 knockdown in KD-fed mice.
An indirect mechanism by which FGF21 may affect LPL
activity is via altered expression of the hepatic angiopoie-
tin-like proteins 3 (ANGPTL3) and 4 (ANGPTL4), which are
known to regulate the activity of LPL (Inaba et al., 2003;
Kaplan et al., 2003; Koishi et al., 2002; Shimizugawa
et al., 2002) and adipocyte lipolysis (Shimamura et al.,
2003). While KD was associated with reduced expression
of ANGPTL3mRNA, hepatic knockdown of FGF21 did not
alter ANGPTL3 expression. Hence, while suppression of
ANGPTL3 could protect against hypertriglyceridemia in
KD-fed mice, this suppression appears not to be medi-
ated by FGF21. Overexpression of ANGPTL4 in liver
induces hypertriglyceridemia by inhibiting LPL activity
(Koster et al., 2005). Though ANGPTL4 expression in liver
was not suppressed by KD, FGF21 knockdown in mice
fed KD led to increased ANGPTL4 expression, raising
the possibility that increased ANGPTL4 expression in liver
could decrease clearance of triglyceride-rich particles.
What about the effect of FGF21 knockdown on ketosis?
A key step in the generation of ketone bodies is mediated
by the mitochondrial form of hydroxymethylglutaryl-
CoA synthase 2 (HMGCS2). While HMGCS2 is regulated
in the short term by posttranslational modification (Quant
et al., 1990), in the long term, transcriptional regulation
occurs, and the gene is a known target of PPARa (Rodri-
guez et al., 1994). The HMGCS2 transcript was consis-
tently induced in microarray analysis of the effects of
KD feeding. Induction of this enzyme was noted in KD-
fed mice infected with control virus, whereas FGF21
knockdown was associated with a return to chow-fed
levels.434 Cell Metabolism 5, 426–437, June 2007 ª2007 Elsevier IncAnother key enzyme that catalyzes the interconversion
of acetoacetate and b-hydroxybutyrate is b-hydroxybuty-
rate dehydrogenase, type 1. This enzyme was also upre-
gulated by KD and was returned to chow-fed levels in
FGF21 knockdown mice. In the presence of elevated in-
tracellular and extracellular concentrations of ketogenic
substrates, this level of expression may be adequate to
maintain a degree of ketosis. Extrahepatic ketogenesis
in the kidney or intestine (Thumelin et al., 1993) may also
maintain circulating ketone levels and is a process that
is induced by high-fat diet. Previously, we noted that KD
increases expression of a number of genes coding for fatty
acid transport proteins; one of these is CD36/fatty acid
translocase (Febbraio et al., 2002; Aitman et al., 1999), im-
plicated in uptake of fatty acids for metabolism in the cell.
FGF21 knockdown reversed KD induction of CD36, yet in-
terestingly did not prevent fat accumulation in the liver.
In conclusion, these data demonstrate that FGF21 is
a nutritionally regulated hormone secreted by the liver.
FGF21 is induced in large part in a PPARa-dependent
manner and plays a critical role in metabolic fuel homeo-
stasis during ketosis. Without full induction of FGF21 ex-
pression while on KD, the machinery required for fatty
acid oxidation is reduced, hepatic ketone output falls, lipe-
mia develops, and massive lipid accumulation occurs
within the liver. Each of these states has previously been
identified as central to the biology of PPARa. Hence,
FGF21 appears to be a vital PPARa-dependent regulator
of metabolism in the ketotic state (see Figure 7). These
findings suggest that subsets of the classical actions
brought about by PPARa are dependent at least in part
upon induction of FGF21. Thus, the effects of this nuclear
receptor, in addition to those that are purely cell autono-
mous, now include actions propagated via paracrine and
endocrine routes.
EXPERIMENTAL PROCEDURES
Animals
Mice strains C57BL/6, 129S4/SvJae-Pparatm1Gonz/J, and 129S1/
SvImJ (control) (The Jackson Laboratory) were maintained at 24C
on a 14/10 hr light/dark cycle. All mice were acclimatized to housing
for 10 days prior to experimentation. Mice were allowed ad libitum ac-
cess to food and water, except where stated otherwise. For microarray
experiments, LabDiet 5008 (PharmaServ) consisting of 6.5% fat,
23.5% protein, and 38.2% carbohydrate (2.5% sucrose) w/w was
used as standard chow. For all other experiments, F6 Rodent Diet
(Harlan Teklad) consisting of 6.5% fat, 24.8%, protein and 39.7% di-
gestible carbohydrate was compared to a ketogenic diet consisting
of 78.9% fat, 9.5% protein, and 0.76% carbohydrate (0% sucrose)
w/w (Bio-Serv). All procedures were approved by and performed in ac-
cordance with the Beth Israel Deaconess Medical Center Institutional
Animal Care and Use Committee.
Microarray Analysis
The transcriptional profiles of samples were probed using the Gene-
Chip Mouse Genome 430 2.0 arrays (Affymetrix) as previously de-
scribed (Kennedy et al., 2007). Following normalization, analysis and
comparison of transcription profiles were performedwith theGeneOn-
tology Tree Machine (GOTM, Vanderbilt University; http://bioinfo.
vanderbilt.edu/gotm/) and gene set enrichment analysis (GSEA, Broad
Institute; http://www.broad.mit.edu/gsea/)..
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FGF21 Mediation of Hepatic MetabolismFigure 7. Schema Detailing Regulation
and Potential Roles of FGF21
Both endogenous lipids and drugs activate
PPARa, which interacts with the retinoid X
receptor (RXR) and then binds to specific
DNA response elements within the promoters
of specific genes to regulate their expression.
A number of genetic programs are stimulated
by PPARa, including those responsible for b-
oxidation and ketosis. FGF21 is a target for
PPARa-mediated expression and is released
from the hepatocyte. FGF21 may have auto-
crine or paracrine roles in the liver or endocrine
effects upon distant targets such as adipose
tissue. The mechanism by which FGF21 exerts
actions on the hepatocyte is unclear, and the
exact receptor or receptor complex for
FGF21 has yet to be determined. Our loss-of-
function studies demonstrate that FGF21 is
required for the expression of a number of
PPARa target genes. This may be due to an
effect of FGF21 signaling on the PPARa signal-
ing system or coregulatory molecules, or due
to distinct effects on gene transcription.RNA Extraction and Real-Time PCR
Total RNA was isolated from tissues with an RNeasy Lipid Tissue Kit
(QIAGEN). One microgram of RNA was used for generation of cDNA
using random hexamers with RETROscript reagents (Ambion). Quan-
titative real-time PCR was performed on a MX3000P thermocycler
(Stratagene), using SYBR Green Master Mix (Applied Biosystems).
Primers used are listed in Table S2. All samples were analyzed in trip-
licate multiplex reactions measuring both the gene of interest (Table
S2) and either 18S RNA or cyclophilin content as an internal control.
Hepatocyte Culture
Hepatocytes were isolated from 8-week-old male C57BL/6 mice by
portal cannulation and collagenase (Sigma) digestion. After purifica-
tion of hepatocytes by differential centrifugation over 22.5% isotonic
Percoll (MP Biomedicals), cells were plated at 1 3 106 cells per well
in BSA coated six-well plates (Becton Dickinson) and allowed to ad-
here for 4 hr in Williams’ E medium containing 10% FBS (GIBCO). Fol-
lowing overnight serum starvation, cells were treated with 100 mM fe-
nofibrate or vehicle in serum-free Williams’ E medium for 24 hr prior to
extraction of RNA as above. BSA conjugates of oleic and linoleic acids
were purchased at a 2:1 molar ratio to albumin in 10%w/v albumin so-
lution (Sigma-Aldrich). Lauric, palmitic, and stearic acid conjugates
were generated at 2:1 molar ratio by dissolving in absolute ethanol
at 60C and then mixing with prewarmed 10% BSA. Conjugated fatty
acids weremixed with culturemedium immediately prior to use to gen-
erate a final concentration of 2% BSA, 0.6 mM fatty acid. Hepatocytes
generated as above were incubated with conjugated fatty acid for
24 hr and extracted for mRNA analysis as above.
Analysis of Metabolites and Circulating Factors
Blood samples were collected on ice and either heparinized and spun
at room temperature prior to storage of plasma at 4C or allowed to
clot and spun at 4C prior to flash freezing of serum in liquid nitrogen.
Serummetabolites weremeasured by small-scale enzymatic assay for
glucose, b-hydroxybutyrate, triglycerides, and cholesterol (Stanbio
Laboratory) and NEFA (Wako Diagnostics). Insulin and leptin were
measured by specific ELISA (Crystal Chem Inc.). FGF21 was mea-
sured by specific radioimmunoassay (Phoenix Pharmaceuticals, Inc.)
with 100% crossreactivity between human and rodent FGF21. FPLC
was performed on pooled samples from eight biological replicates
with SMART micro-FPLC (Amersham Biosciences) consisting ofCa Superose 6 PC 3.2/30 column (Amersham Biosciences) equilibrated
in 13 PBS buffer. The flow rate was maintained constant at 50 ml/min.
The sample was injected 2 min after the beginning of the procedure,
and fractions were collected from 20 to 45 min. A wash of at least
20 min was included before each sample injection. FPLC fractions
were subsequently analyzed for triglyceride and cholesterol concen-
trations by enzymatic assay (Wako Diagnostics).
Short Hairpin Design and Adenovirus Production
The sequence of murine FGF21 was analyzed for suitable sequences
for RNAi targeting. Double-stranded oligonucleotides encoding
shRNA were generated, annealed, and cloned into a pENTR/U6 entry
vector (Invitrogen). Entry clones targeting either LacZ or five different
areas of murine FGF21 were produced and screened in an in vitro as-
say for ability to knock down FGF21 expression by cotransfection with
an FGF21 expression vector in heterologous and homologous cell lines
(Figure S1). LacZ and three entry vectors were used to generate one
control and three shRNA expression clones by LR recombination reac-
tion with the E1- and E3-deleted pAd/BLOCK-iT-DEST vector (Invitro-
gen). Sequences used were 50-GGGATTCAACACAGGAGAAAC-30
(shFGF21) and a proprietary shLacZ targeting sequence (Invitrogen).
Adenoviruses were generated by transfection of 293A cells vector
digested with PacI in order to expose left and right viral inverted termi-
nal repetitions and removal of the bacterial sequences. After plaque
selection and amplification, all viruseswere purified on a discontinuous
CsCl gradient. Viral particles were introduced at stated titer by tail-vein
injection.
In Vivo Effect of shFGF Adenovirus
Groups of eight C57BL/6 mice were fed either chow or KD for a mini-
mum of 4 weeks in order to fully acclimate them to the diet, injected
with shFGF21 or control adenovirus, and subsequently observed daily.
Four days after injection, mice were sacrificed by terminal anesthesia
and exsanguination. Tissues were harvested and snap frozen in liquid
nitrogen and subsequently stored at 80C prior to analysis. In order
to establish the effect of FGF21 knockdown on triglyceride clearance,
a separate cohort of adenovirus-injected animals were injected i.p.
with 500 mg/kg of the LPL inhibitor tyloxapol (Sigma) after sampling
of blood from the tail vein (Petit et al., 2007). Plasma triglycerides
were subsequently measured at 1, 2, 4, and 6 hr after injection, at
which time animals were sacrificed.ell Metabolism 5, 426–437, June 2007 ª2007 Elsevier Inc. 435
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All results are expressed as mean ± SEM. Statistical comparisons of
groups were made using an unpaired Student’s t test.
Supplemental Data
Supplemental Data include two tables and two figures and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/5/6/426/DC1/.
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